Introduction
Reference [No.] | Type of endometriosis [sample type and size] | Major technique(s) employed | Salient observations |
---|---|---|---|
Noble et al., 1997 [14] | OE [CE (n = 7), EE (n = 2), EC (n = 4)] | Biochemical assay, qRTPCR | Low basal activity in EE but not reported for CE. Details of fertility status and phase of cycle was not provided. |
Velasco et al., 2006 [15] | PE, OE [CE (n = 12), EE (n = 54), EC (n = 61)] | IHC | No immunopositive aromatase detected in CE and EE, while 61% of EC samples showed aromatase activity. Higher in secretory phase and in severe stage. No combinatorial analysis done. No details of fertility history was provided. |
Aghajanova et al., 2009 [16] | PE, OE, DIE [CE (n = 13, EE (n = 29)] | qRTPCR, IHC | Aromatase mRNA expression was 14.5-fold upregulated, with no change in STAR, CYP11A1,HSD3B1, 2, CYP17A1 and HSD17B1, 2 in EE as compared to CE during mid-secretory phase of cycle. Fertility status was undefined. |
Colette et al.,2009 [17] | OE, PE, RV [CE (n = 10), EE_EC (n = 56)] | IHC, WB in CE, EE and EC during both phases of menstrual cycle | Aromatase mRNA and protein were not detectable cycle. Perls’ stainb positive siderophages were immunopositive for aromatase. Fertility history was not reported. |
Delvoux et al., 2009 [18] | OE, DIE, SE [CE (n = 20), EE_EC (n = 14)] | Biochemical assay, HPLC | Aromatase activity was not detected in any tissue.No difference in reductive-oxidative activities of 17β-HSDs between CE and EE was observed. Details of menstrual cycle phase and fertility history were not reported. |
Noel et al., 2011 [19] | PE, OE, DIE[CE (n = 16), EE_EC (n = 72)] | IHC. No details of stages of endometriosis, phases of menstrual cycle | No immunoreactivity of SF-1 was observed in EE. No details of stages of endometriosis, phases of cycle and fertility history was provided. |
Huhtinen et al. 2012 [12] | PE, OE, DIE [CE (n = 11), EE (n = 17), EC (n = 18)] | qRTPCR | Generally, very low expression levels for mRNAs of CYP19A1 and HSD17B1, while high expression levels for HSD17B2, more during secretory phase, was detected in CE and EE with no difference between the groups. No details of stages of endometriosis and fertility history was provided. |
Reference[No.] | Type of endometriosis [sample type and size] | Major technique(s) used | Salient observations with remarks |
---|---|---|---|
Lessey et al., 1989 [20] | PE, OE, DIE [CE (n = 25), EE (n = 12), EC (n = 9)] | IHC | No difference was observed in the ER and PGR levels between CE and EE, as well as, between EE and EC. Analysis between CE and EE was not done based on phases of menstrual cycle despite tissue samples were collected during both cycle phases. Fertility history was not provided. |
Burney et al., 2007 [10] | PE, OE [CE (n = 16), EE (n = 21)] | Microarray qRTPCR | 2.3-fold downregulation of PGR mRNA was observed in EE compared to CE. Analysis between CE and EE was not done based on phases of menstrual cycle despite tissue samples were collected during both phases of menstrual cycle. Fertility history was not provided. |
Bukulmez et al., 2008 [21] | PE, OE [CE (n = 8), EE (n = 12), EC (n = 14)] | qRTPCR, IHC, WB | Lower ESR1:ESR2 mRNA ratio was observed in CE and EE than EC along with higher immunopositivity for ERβ in EC. Lower PRA and PRB was observed in EC as compared to EE and CE. Analysis based on phases of menstrual cycle was not reported despite tissue samples were collected during both cycle phases. No information on stages of endometriosis and fertility history was provided. |
Cavallini et al., 2011 [22] | OE [CE (n = 10), EE_EC (n = 10)] | qRTPCR, ELISA, IHC | Protein expression of ERα was higher in EE than CE and EC with similar expressions in mRNA profiles. Protein expression of ERβ was lower in EE than EC and CE. Higher PGR mRNA and immunopositivity was observedin EE than in EC. No data for stages of endometriosis, phases of menstrual cycle and fertility history was provided. |
Huhtinen et al., 2012 [12] | PE, OE, DIE [CE (n = 15), EE (n = 37), EC (n = 41)] | qRTPCR | ESR1 mRNA expression was lower in both phases of menstrual cycle in EC than CE. ESR1 mRNA was found to be lower in secretory phase as compared to proliferative phase in EE. ESR2 mRNA was higher in EC (OE and DIE) than CE in both phases. No data for stages of endometriosis and fertility history was provided. |
Materials and methods
Patient selection
Group [N] | Subgroup (n) | Description | Age (Mean ± SD) | BMI (Mean ± SD) | Cycle daya (Mean ± SD) | Number of samples used in each experiment | ||
---|---|---|---|---|---|---|---|---|
qRTPCR | WB | ELISA | ||||||
Control (C) [28] | FPC (13) | Fertile Proliferative Control | 25.3 ± 1.2 | 20.1 ± 1.1 | 8.2 ± 1.2 | 10 | 4 | 4 |
IFPC (6) | Infertileb Proliferative Control | 26.8 ± 2.1 | 19.8 ± 1.2 | 10.5 ± 0.9 | 4 | 4 | 4 | |
FSC (6) | Fertile Secretory Control | 32.4 ± 1.7 | 22.2 ± 1.3 | 24 ± 1.3 | 4 | 4 | 4 | |
IFSC (7) | Infertileb Secretory Control | 32.5 ± 2.7 | 22.4 ± 0.8 | 22 ± 1.8 | 4 | 4 | 4 | |
Ovarian | FPU (17) | Fertile Proliferative Eutopic | 31.9 ± 1.3 | 20.3 ± 0.9 | 9 ± 0.8 | 11 | 7 | 4 |
endometriosis | IFPU (13) | Infertileb Proliferative Eutopic | 27.2 ± 1.7 | 22.1 ± 1.3 | 11 ± 1.3 | 7 | 4 | 4 |
(OE) [29] | FSU (11) | Fertile Secretory Eutopic | 34.4 ± 1.8 | 22.6 ± 1.7 | 22 ± 1.6 | 6 | 7 | 4 |
IFSU (11) | Infertileb Secretory Eutopic | 19.6 ± 2.3 | 21.8 ± 1.1 | 23 ± 1.9 | 9 | 5 | 4 |